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Schizophrenia is a disabling, chronic psychiatric disorder with a prevalence rate of 0.5–
1% in the general population. Symptoms include positive (e.g., delusions, hallucinations),
negative (e.g., blunted affect, social withdrawal), as well as cognitive symptoms (e.g.,
memory and attention problems). Although 75–85% of patients with schizophrenia report
cognitive impairments, the underlying neuropharmacological mechanisms are not well
understood and currently no effective treatment is available for these impairments. This
has led to the Measurement and Treatment Research to Improve Cognition in Schizophre-
nia (MATRICS) initiative, which established seven cognitive domains that are fundamentally
impaired in schizophrenia.These domains include verbal learning and memory, visual learn-
ing and memory, working memory, attention and vigilance, processing speed, reasoning
and problem solving, and social cognition. Recently, a growing number of studies have
been conducted trying to identify the underlying neuropharmacological mechanisms of
cognitive impairments in schizophrenia patients. Specific cognitive impairments seem to
arise from different underlying neuropharmacological mechanisms. However, most review
articles describe cognition in general and an overview of the mechanisms involved in these
seven separate cognitive domains is currently lacking. Therefore, we reviewed the under-
lying neuropharmacological mechanisms focusing on the domains as established by the
MATRICS initiative which are considered most crucial in schizophrenia.
Keywords: pharmacology, schizophrenia, cognition, MATRICS, neurotransmitters
INTRODUCTION
Schizophrenia is a disabling, chronic psychiatric disorder with
a prevalence rate of 0.5–1% in the general population. Symp-
toms include positive and negative symptoms and disorganiza-
tion. Approximately 75–85% of the schizophrenia patients report
cognitive impairments as well (1). Although this aspect of schiz-
ophrenia was already described by Kraepelin nearly a century
ago, cognitive impairments have long been under-identified as
a symptom of schizophrenia and relatively little research has been
conducted on this topic. Previous research showed that cogni-
tive functioning is strongly associated with functional outcome in
schizophrenia [e.g., skill acquisition in psychosocial rehabilitation
treatment, demonstration of ability to solve simulated interper-
sonal problems, and community functioning (2, 3)]. Cognitive
impairments often precede the onset of other symptoms and per-
sist after other psychotic symptoms have been effectively treated
(4). Furthermore, severity of cognitive impairments is predictive
of poorer medication compliance (5), treatment adherence (6),
and increased tendency for relapse in first-episode patients (7).
At present, no effective treatment is available as existing (antipsy-
chotic) medication mainly targets positive symptoms and does
not improve cognition. Although it is sometimes assumed by clin-
icians (possibly due to marketing) that atypical antipsychotics
are superior to typical antipsychotics, results from recent studies
contradict this theory. Presently available guidelines for treatment
of schizophrenia, such as the NICE (8), PORT (9), and WFSBP
(10) guidelines, indicate that there is no superiority of atypical
antipsychotics on positive symptoms with the exception of clozap-
ine, and instead state that use of antipsychotics should be evaluated
based on their side effects. Since cognitive dysfunction is associated
with functional outcome, development of an effective interven-
tion strategy for these symptoms and corresponding guidelines is
essential, as such guidelines are currently still lacking.
Lack of effective treatment strategies has over recent years
led to an increase in studies investigating underlying neurobio-
logical mechanisms of cognitive impairments and potential new
pharmacological targets to enhance cognition in schizophrenia.
Research has mainly focused on the role of neurotransmitters
such as dopamine, serotonin,γ-aminobutyric acid (GABA), gluta-
mate, and acetylcholine. Previous research indicated that specific
cognitive impairments seem to arise from different underlying
neurobiological mechanisms (11). For example, the prefrontal
cortex (PFC) has been implicated in the executive functioning
aspect of cognition (12) whereas the hippocampus has been
linked to, e.g., episodic memory (13). This suggests that spe-
cific pharmacological agents could enhance domains of cogni-
tion differentially. Nonetheless, still little is known about the
underlying neurobiology of cognition. Knowledge about these
neurobiological mechanisms is highly necessary for development
of new pharmacological intervention strategies.
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Table 1 | Pharmacological agents used and their main mechanism of
action.
General
pharmacological
domain
Pharmacological
agent
Agents main mechanism
of action
Antipsychotics Haloperidol D2 antagonist
Chlorprothixene D2 antagonist
Perazine D2 antagonist
Flupenthixol D2 antagonist
Amisulpride D2/D3 antagonist
Risperidone D2 and 5-HT2a antagonist
Paliperidone D2 and 5-HT2a antagonist (active
metabolite of risperidone)
Olanzapine D2 and 5-HT2a antagonist
Loxapine D2 and 5-HT2a antagonist
Sertindole D2 and 5-HT2a antagonist
Ziprasidone D2 and 5-HT2a antagonist
Quetiapine D2 and 5-HT2a antagonist partial
5-HT1a agonist
Aripiprazole 5-HT2a antagonist and partial D2
agonist and partial 5-HT1a agonist
Perospirone D2 and 5-HT2a antagonist and
5-HT1a agonist
Clozapine D2, D4, and 5-HT2a antagonist
partial 5-HT1a agonist (metabolite
shows weak partial agonistic
effects on D2 and D3)
BL-1020 D2 and 5-HT2a antagonist GABAA
agonist
Dopaminergic Dihydrexidine D1 agonist
Serotonergic Ondansetron 5-HT3a antagonist
Tandospirone 5-HT1a agonist
Tropisetron 5-HT3a antagonist
Fluvoxamine Reuptake inhibition and sigma-1
receptor agonist
Citalopram Reuptake inhibition
Cholinergic AZD3480 nicotinic α4β2 agonist
DMXB-A Partial nicotinic α7 agonist
Donepezil Acetylcholinesterase inhibition
Galantamine Acetylcholinesterase inhibition
Rivastigmine Acetylcholinesterase inhibition
Glutamatergic Minocycline (Mainly used as antibiotic) blocks
nitric oxide induced neurotoxicity
D-Cycloserine NMDA partial agonist
Lamotrigine Glutamate release regulation
Topiramate AMPA/kainite antagonist
GABAergic MK-0777 GABA α2/α3 agonist
Lorazepam GABAA agonist
Flumazenil GABAA antagonist
Noradrenergic Atomoxetine Reuptake inhibition
(Continued)
General
pharmacological
domain
Pharmacological
agent
Agents main mechanism
of action
Stimulants D-Amphetamine Dopamine/norepinephrine
releaser thus indirect dopamine
agonist
Modafinil Unknown
Armodafinil Unknown
Other domains Mifepristone Glucocorticoid receptor
antagonist
Sildenafil PDE5 inhibition
To improve cognition research in schizophrenia the Measure-
ment and Treatment to Improve Cognition in Schizophrenia
(MATRICS) was developed. The MATRICS identified seven cog-
nitive domains that are fundamentally impaired in schizophre-
nia: verbal learning and memory, visual learning and memory,
working memory, attention and vigilance, processing speed, rea-
soning and problem solving, and social cognition (14). It was
decided that cognition research in schizophrenia should mainly
focus on these domains in order to identify the neurobiolog-
ical mechanisms, ultimately to facilitate development of new
pharmacological treatment strategies.
Although specific domains of cognition have been identified,
most studies tend to describe cognition in general terms using a
composite score. Currently, a review differentiating between sep-
arate MATRICS domains is lacking. Therefore, the aim of this
review is to provide an outline of the underlying neuropharmaco-
logical mechanisms of each individual cognitive domain. We will
focus on pharmacological intervention studies which used vali-
dated instruments to measure the effect on the MATRICS cognitive
domains.
METHODS
SEARCH STRATEGY
A literature search was conducted in medical database PubMed.
The following keywords were used: “pharmacology,” “schizophre-
nia,” and “Cognition.” Subsequently, a separate search was con-
ducted for each individual domain combining the keywords“phar-
macology” and “schizophrenia” with the following keywords:“ver-
bal learning,”“verbal memory,”“visual learning,”“visual memory,”
“working memory,” “attention,” “vigilance,” “processing speed,”
“reasoning,”“problem solving,” and “social cognition.”
INCLUSION AND EXCLUSION CRITERIA
Papers that met the following inclusion criteria were included: (1)
original research papers, both single challenge and clinical trials
(full text available); (2) published in English; (3) use of a pharma-
cological intervention (pharmacological interventions used and
their main mechanism of action are displayed in Table 1); (4)
use of validated cognitive tests to measure one or more of the
MATRICS domains; (5) subjects were patients with schizophrenia;
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and (6) were published between January 2000 and May 2013.
Papers were excluded if: (1) only healthy subjects were included;
(2) also schizoaffective disorders and other psychotic disorders
were included; (3) cognitive domains were measured with non-
validated tests; (4) cognitive domains other than the MATRICS
domains were measured; and (5) only a composite score of
cognition was reported.
RESULTS
In total, the search strategy yielded 938 articles of which 293 arti-
cles were found using the keywords “pharmacology,” “cognition,”
and “schizophrenia.” The separate searches yielded 158 articles
for verbal learning and memory, 85 for visual learning and mem-
ory, 100 for working memory, 234 for attention and vigilance,
22 for processing speed, 17 for reasoning and problem solving,
and 29 for social cognition. After final screening 44 articles were
included for verbal learning and memory, 26 for visual learn-
ing and memory, 43 for working memory, 22 for attention and
vigilance, 31 for processing speed, 30 for reasoning and prob-
lem solving, and 7 for social cognition. Study characteristics and
specifics are shown in Table 2 (studies investigating antipsychotics)
and Table 3 (studies investigating non-antipsychotic intervention
strategies).
VERBAL LEARNING AND MEMORY
It has been proposed that impairments in verbal learning and
memory are one of the most consistent cognitive deficits seen in
schizophrenia (15) and is one of the most examined cognitive
domains in these patients. A majority of the 44 included stud-
ies investigated the effects of typical and atypical antipsychotic
medication on verbal learning and memory.
In the past, it was assumed that atypical antipsychotics are
superior to typical antipsychotics in enhancing cognition in schiz-
ophrenia due to their affinity for both dopamine D2 receptors
and serotonin 5-HT2A receptors (16, 17). However large studies
such as the Clinical Antipsychotic Trials of Intervention Effective-
ness (CATIE) (18) and the European First Episode Schizophrenia
Trial (EUFEST) (19) did not find differences between typical and
atypical antipsychotics in cognitive enhancing effects. This the-
ory was tested by Wagner et al. (16) who compared olanzapine,
a dopamine D2, and serotonin 5-HT2A antagonist, to amisul-
pride, a dopamine D2/D3 antagonist in 52 patients. No significant
differences were found after 8 weeks between the two groups in
terms verbal memory; both groups improved on verbal learning
and memory tasks. Olanzapine was compared to risperidone and
haloperidol by Purdon et al. (20). Although not significant after
corrections for multiple comparisons, olanzapine was found to
be superior to risperidone and haloperidol in enhancing verbal
learning and memory.
The atypical antipsychotic ziprasidone was found to improve
verbal learning and memory after 12 weeks of monotherapy (21).
However, the study did not include a control group and prac-
tice effects were not adequately controlled for. Therefore the
results have to be interpreted with caution. A study comparing the
effects of risperidone and haloperidol on verbal memory found
that performance on a verbal memory task remained essentially
unchanged in both groups (22). Since the authors did not include a
non-medicated schizophrenia group but included a healthy group
as control this mainly provides evidence that there is no difference
between risperidone and haloperidol. Nevertheless it suggests that
both medications did not cause a clinically relevant enhancement
of verbal memory. However,Harvey et al. (23) compared the effects
of risperidone and quetiapine and found improvement in verbal
memory in both treatment groups. The dropout rate of 57% in
this trial was high which may have caused a selection bias. These
results are not consistent with other findings. A small study with
substantial methodological shortcomings by Purdon et al. (24)
found no effect of haloperidol and quetiapine. Velligan et al. (25)
also compared quetiapine to haloperidol and found that patients
in the quetiapine group improved to a greater extent than the
patients in the haloperidol group. However, these findings were
not significant after correction for multiple comparisons. More-
over, Kivircik Akdede et al. (26) did not find improvement on
a verbal learning and memory task after 8 weeks of quetiapine
treatment.
Kim et al. (27) found that switching from oral atypical antipsy-
chotics to depot risperidone led to significant improvement in
verbal learning and memory. However, they also did not include
a control group and did not correct for possible practice effects.
Furthermore a high percentage of the patients dropped out in an
early stage of the study which could have caused a bias in the
sample. Despite these limitations, their results are supported by
Suzuki and Gen (28) who also found an improvement in verbal
learning and memory in patients treated with depot risperidone
compared to patients who received haloperidol treatment (depot).
However, the differences between these two treatments might be
caused by the high rate of anticholinergic co-medication in the
haloperidol group which is well known for its adverse effects on
cognition (29). Additionally, improvement in verbal learning and
memory was found by Surguladze et al. (30) with both depot
risperidone and typical antipsychotics (depot). Performance did
not significantly differ between the groups. However, they did
not control for practice effects. Therefore improvement cannot
reliably be attributed to medication effects. In addition, Kim
et al. (31) found that compared to patients using risperidone,
verbal memory improved more in patients using paliperidone
extend release (ER), an active metabolite of risperidone with an
extended delivery system that decreases fluctuations in serum drug
concentrations.
Hence, the theory that atypical antipsychotic medications are
superior to typical antipsychotics in enhancing verbal learning and
memory is not supported by these findings. Nonetheless, some
of the atypical antipsychotics, especially risperidone depot, have
shown beneficial effects on this aspect of cognition.
Results regarding the effects of clozapine on verbal learn-
ing and memory are inconclusive. Three studies which investi-
gated the effects of clozapine on verbal learning and memory
were found. Purdon et al. (32) reported significant improve-
ment in verbal learning and memory after treatment with cloza-
pine. Their results were not replicated by Ertugrul et al. (33)
and Sumiyoshi et al. (34) as both of these studies did not find
improvement in verbal memory in clozapine-treated patients.
This discrepancy in findings could be due to methodological
differences such as different test batteries and trial duration.
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Moreover, the study by Purdon et al. (32) did not correct for possi-
ble practice effects and since they did not include a control group,
improvement in verbal memory cannot be reliably attributed to
the effects of clozapine. Thus, although results are inconclusive,
at present no convincing evidence is available for the effective-
ness of clozapine in enhancing verbal learning and memory in
schizophrenia.
Geffen et al. (35) compared the effects of 10 and 20–30 mg of
BL-1020, a new antipsychotic drug, to risperidone and placebo.
BL-1020 is an antagonist for D2 en 5-HT2a receptors and ago-
nist for GABAA receptors (35). Post-mortem studies have found
altered GABAergic transmission in schizophrenia, predominantly
in the PFC (36, 37). Treatment with 20–30 mg BL-1020 was found
to improve performance on a verbal learning memory task com-
pared to placebo, whereas 10 mg of BL-1020 and risperidone did
not have enhancing effects compared to placebo. A substantial
number of patients, especially in the risperidone group, received
anticholinergics as well, which could have influenced the results.
Although the findings described above do not support the the-
ory that blocking the 5-HT2A receptors improves verbal learning
and memory, a role for serotonin in this domain of cognition
cannot be ruled out. Sumiyoshi et al. (38) found a significant
improvement on verbal memory after adjunctive tandospirone
(a 5-HT1a agonist) treatment compared to patients who did not
receive adjunctive tandospirone. Riedel et al. (39) and Bervoets
et al. (40) both found a significant improvement in verbal memory
in patients treated with aripiprazole, an atypical antipsychotic drug
with partial D2 agonistic and antagonistic and 5-HT2a antagonis-
tic properties in addition to partial agonistic activity at the 5-HT1a
receptors. However, this is contradicted by Suzuki et al. (41) who
compared the effects of aripiprazole, olanzapine, and perospirone
on verbal memory. None of the three conditions showed signif-
icant changes in verbal memory scores and no differences were
found between the three treatment conditions. Moreover, arip-
iprazole added to atypical antipsychotics did not improve verbal
learning and memory in a trial by Yasui-Furukori et al. (42). This
discrepancy in findings could be due to practice effects in the stud-
ies of Riedel et al. (39) and Bervoets et al. (40), since both studies
did not include a control group and did not correct for possi-
ble practice effects. Furthermore, different tasks were used which
makes it difficult to directly compare the results.
The role of the serotonin 5-HT3a receptor in verbal learning
and memory has been examined as well. Akhondzadeh et al. (43)
and Levkovitz et al. (44) investigated the effects of ondansetron,
a serotonin 5-HT3a receptor antagonist, added to respectively
risperidone and clozapine treatment, and found no enhancing
effects on verbal learning and memory. However, the sample size
of both studies was small. In contrast to these results, Zhang et al.
(45) did find improvement in verbal memory after add-on tro-
pisetron (a 5-HT3a receptor antagonist and nicotinic α7 agonist)
to risperidone treatment compared to placebo. This discrepancy
in findings could be explained by the fact that the two studies
used different pharmacological interventions. Both Akhondzadeh
et al. (43) and Levkovitz et al. (44) administered ondansetron
whereas Zhang et al. (45) used tropisetron. Since ondansetron has
been found to have low affinity for the nicotinic α7 receptors (46),
the positive effects of tropisetron on verbal learning and memory
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could be due to its nicotinic α7 agonistic properties rather than its
antagonistic effects on the 5-HT3a receptors.
Effects of a selective serotonin reuptake inhibitor (SSRI) were
examined by Friedman et al. (47) who added citalopram to treat-
ment with atypical antipsychotics but found no improvement in
verbal learning and memory.
Thus, although results are inconclusive there is preliminary
evidence of positive effects of 5-HT1a agonists, but not 5-HT3a
antagonists on verbal learning and memory in schizophrenia.
One study examined the effects of a dopamine D1 agonist on
verbal learning and memory in schizophrenia. George et al. (48)
administered dihydrexidine as a pharmacological challenge and
found no effects of dihydrexidine on verbal learning and memory.
The role of the neurotransmitter acetylcholine in cognition has
been widely investigated and established (36). Post-mortem, a cor-
relation was found between cognitive impairment and decreased
levels of brain choline acetyltransferase in schizophrenia (49).
Post-mortem studies have shown changes in both muscarinic and
nicotinic acetylcholine receptors in patients with schizophrenia
(50). Velligan et al. (51) conducted a trial to assess the effects
adjunctive therapy with the selective nicotinic α4β2 receptor ago-
nist AZD3480 on verbal learning and memory in patients but
found no improvement. An important limitation of this study
is that only patients who smoked were included. Therefore, the
lack of effect could be due to desensitization of the nicotinic
receptors caused by chronic tobacco use. However, Freedman
et al. (52) also did not find an improvement in verbal learn-
ing and memory after administration of the partial nicotinic α7
agonist DMXB-A, added to antipsychotic treatment in patients,
who abstained from nicotine at least 1 month prior to participa-
tion. Studies using acetylcholinesterase (enzyme that breaks down
acetylcholine, thereby increasing acetylcholine levels) inhibitors
(AChE-Is) as adjunctive therapy to antipsychotic medication also
found no improvement on verbal learning and memory (53–58).
These results suggest that acetylcholinesterase inhibitors do not
effectively enhance verbal memory in patients with schizophre-
nia. However, all studies used a small sample size and one study
included patients who were taking anticholinergic medication as
well. This could have influenced the outcome of the study. Another
important limitation is that none of these studies controlled for the
effects of smoking. Hence, although there is theoretical evidence
for a role of acetylcholine in cognition, various (possibly under-
powered) intervention studies have not yielded positive results.
Since Zhang et al. (45) found improvement in verbal learning and
memory after adjunctive tropisetron treatment, it remains pos-
sible that enhancement of verbal learning and memory can be
achieved with nicotinic α7 agonists while simultaneously blocking
the 5-HT3a receptors.
The role of the neurotransmitters GABA and norepinephrine
in verbal learning in memory has also been investigated. Buchanan
et al. (59) found no improvement in verbal learning and memory
with adjunctive MK-0777, a partial GABA α2/α3 agonist, therapy
to antipsychotics. However, the authors argue that a lack of effect
may be due to the fact that MK-0777 is a weak GABAα2/α3 agonist.
A pilot study by Friedman et al. (60) found no effects of the nor-
epinephrine reuptake inhibitor atomoxetine, on verbal memory
when added to treatment with atypical antipsychotics.
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Hence, although positive effects were found with the antipsy-
chotic BL-1020 with GABAA agonistic properties, the available
studies were not able to detect positive effects of both a partial
GABA α2/α3 agonist and a norepinephrine reuptake inhibitor on
verbal learning and memory. Nonetheless, these results suggest
that GABAA receptors may be a potential target for future studies
in verbal learning and memory.
Effects of the psychostimulant armodafinil were investigated
by Kane et al. (61). Armodafinil is a longer-lasting isomer of
modafinil, which is an alertness-promoting medication with
mechanisms of action different from those of amphetamine (62)
and has been found to improve cognition in healthy subjects and
adults with ADHD (63). However, the exact mechanisms of action
are complex and not entirely understood (64). Armodafinil, added
to atypical antipsychotics, did not enhance verbal learning and
memory.
The effects of several other pharmacological interventions on
verbal learning and memory in schizophrenia have been inves-
tigated. Six months of daily creatine administration added to
antipsychotic treatment did not have beneficial effects on verbal
learning and memory (65). Effects of adjunctive mifepristone,
a glucocorticoid receptor (GR) antagonist, on verbal learning
and memory was examined by Gallagher et al. (66). They found
no improvement in this domain of cognition. Goff et al. (67)
examined the effects of sildenafil, a phosphodiesterase 5 (PDE5)
inhibitor used to treat erectile dysfunction, on verbal learning and
memory. PDE5 inhibitors increase cyclic guanine monophosphate
(cGMP) which is thought to modulate long-term potentiation.
They found single dose of 50 and 100 mg not to improve verbal
learning and memory. On the other hand, Feifel et al. (15) found
that patients who received intranasal oxytocin for 3 weeks per-
formed better on a verbal learning and memory task. Additionally,
Stone et al. (68) found that additional glucose administration in
patients who were stable on clozapine, enhanced verbal learning
and memory. All studies used a small sample and the dropout rate
in the study by Feifel et al. (15) was 25%. Moreover, the majority
of the patients in the study of Stone et al. (68) received addi-
tional medication besides clozapine. Therefore the effect cannot
be attributed to a unique interaction of clozapine and glucose.
To summarize, the proposed superior effect on verbal learn-
ing and memory of atypical to typical antipsychotics, is not
supported by the available data and any effect does not result
from blocking the 5-HT2a receptors. Despite the fact that multi-
ple studies describe a role of acetylcholine in cognition, nicotinic
receptor agonist and acetylcholinesterase inhibitors do not seem
to effectively improve verbal learning and memory in schizo-
phrenia. However, some positive results have been found with
risperidone depot, possibly because of medication compliance.
In addition, serotonin 5-HT1a receptors and GABAA receptors
may be molecular targets for enhancing this aspect of cognition.
Additionally, there is preliminary evidence that adjunctive oxy-
tocin and glucose treatment may be beneficial in enhancing verbal
learning and memory. However, results have to be interpreted
with care as the available studies are mostly pilot studies which,
although important in early stages of research, inherently suffer
from methodological shortcomings.
VISUAL LEARNING AND MEMORY
Compared to verbal learning and memory, considerably less
research has been conducted regarding visual learning and mem-
ory in schizophrenia. Results of studies that examined the effects
of antipsychotic medication on visual learning and memory are,
similar to verbal learning and memory, indecisive. Tyson et al.
(17) compared the effects of atypical antipsychotic medication
with high and low affinity for the 5-HT2a receptors on visual
learning and memory. Patients treated with risperidone, olanza-
pine, and clozapine were assigned to the high-affinity group and
patients using quetiapine and amisulpride were assigned to the
low affinity group. Performance on visual memory tasks improved
in patients in the low affinity group whereas performance in the
high-affinity group declined. A limitation is that the authors did
not correct for multiple testing. However, the effects were already
present after 9 months of treatment and show a consistent pattern.
Since performance declined in the high-affinity group, it is not
likely that the improvement in the low affinity group is driven by
practice effects. However,Rollnik et al. (69) found atypical antipsy-
chotics (olanzapine, risperidone, or clozapine) to be superior to
typical antipsychotics (haloperidol, chlorprothixene, perazine, or
flupenthixol) in improving visual learning and after 3 weeks of
treatment, although at the final assessment, this difference was no
longer significant. Purdon et al. (20) compared the effects of olan-
zapine, risperidone, and haloperidol. After correction for multiple
comparisons, no significant differences were found between the
three treatment conditions; visual learning and memory did not
improve in all three groups. As mentioned earlier, lack of effect
could be caused by concomitant anticholinergic treatment and
the small sample size.
Two studies compared the effects of haloperidol to respectively
quetiapine (24) and risperidone (70). In both studies haloperidol
and both quetiapine and risperidone were found not to enhance
visual learning and memory. However, a substantial number of
patients in both studies were treated with anticholinergics in addi-
tion to antipsychotics, which could have influenced the results.
Surguladze et al. (30) found no differences in visual learning
and memory between depot risperidone and a typical antipsy-
chotic depot treatment, although performance in both groups
improved. As discussed earlier, it cannot be ruled out that this
improvement is caused by practice effects rather than the effects
of medication.
Although results are inconclusive, clozapine does not seem to
effectively enhance visual learning and memory. A study by Ertu-
grul et al. (33) did not find improvement with clozapine whereas
Purdon et al. (32) found significant improvement on performance
on one of three assessed visual memory subtests. However, this
study has important limitations, which were described earlier.
Treatment with aripiprazole did not significantly improve
visual learning and memory in the study by Riedel et al. (39).
Tandospirone, which like aripiprazole has serotonin 5-HT1a ago-
nistic properties, also did not significantly enhance visual learning
and memory in the study of Sumiyoshi et al. (38). These findings
suggest that stimulating the serotonin 5-HT1a receptors does not
enhance visual learning and memory in schizophrenia. However,
the serotonin 5-HT3a receptors may play a role in visual memory
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in schizophrenia. Both Akhondzadeh et al. (43) and Levkovitz
et al. (44) found visual learning and memory to improve with
adjunctive ondansetron treatment. Although both studies did not
correct for multiple testing and possible practice effects, visual
memory was the only aspect of the cognitive domains measured
that improved in both studies. Adjunctive tropisetron treatment
on the other hand did not enhance visual memory (45). As men-
tioned earlier, tropisetron is both a 5-HT3a antagonist and partial
nicotinic α7 agonist whereas ondansetron has low affinity for the
nicotinic α7 receptors (46). Hence, the 5-HT3a receptors may play
a role in visual learning and memory. However, enhancement of
this aspect of cognition may depend on blockade of nicotinic α7
receptors. The 5-HT1a receptor does not seem to be a promising
target for enhancing visual learning and memory.
A preliminary study by Niitsu et al. (71) investigated the effect
of the SSRI fluvoxamine, a sigma-1 receptor agonist, on cognition
and found it not to enhance visual learning and memory. These
preliminary results indicate sigma-1 receptor agonism does not
enhance visual learning and memory in schizophrenia patients.
Studies investigating the role acetylcholine in visual learning
and memory in schizophrenia have not yielded positive results.
Selective nicotinic α4β2 receptor agonist AZD3480 and partial
nicotinic α7 agonist DMXB-A both did not enhance visual learn-
ing and memory when added to antipsychotic treatment (51,
52). As mentioned earlier, the lack of effect in the study of Vel-
ligan et al. (51) could be due to desensitization of the nicotinic
receptors caused by chronic tobacco use since only smokers were
included. Studies conducted with acetylcholinesterase inhibitors
do not report positive results either. Although Lee et al. (54) found
improvement on the recognition subtest of Rey Complex Figure
Test (RCTF) with galantamine, the other aspects of the task did
not improve. Studies using donepezil also did not find improve-
ment in visual learning and memory (50, 53, 55). Hence, both
nicotinic receptor agonists and acetylcholinesterase inhibitors do
not seem to effectively enhance visual learning and memory in
schizophrenia.
Based on preliminary results of Buchanan et al. (59), GABA
does not seem to enhance visual learning and memory in schizo-
phrenia as they found no improvement with partial GABAA α2/α3
agonist MK-0777. However, this is the only study investigating the
role of GABA in visual learning and memory and MK-0777 is a
weak GABA α2/α3 agonist.
The possible enhancing effect of psychostimulant drugs on
visual learning and memory has been investigated in schizophrenia
as well. A single dose of d-amphetamine, an indirect dopamine D1
agonist, did not improve visual learning and memory (72). A single
administration of modafinil did not significantly enhance visual
memory either (63). In addition, adjunctive armodafinil treatment
did not improve visual learning and memory (61). Hence, based
on these findings d-amphetamine and modafinil do not seem to
be promising intervention strategies for enhancing visual learning
and memory.
Results of other pharmacological interventions on visual learn-
ing and memory are mixed. Gallagher et al. (66) found no
improvement after adjunctive mifepristone (a GR antagonist)
treatment. The effect of adjunctive creatine treatment was inves-
tigated by Kaptsan et al. (65) but they found it not to enhance
visual learning and memory. Levkovitz et al. (73) investigated the
effects of minocycline, a second generation tetracycline with anti-
inflammatory and antimicrobial effects. Minocycline modulates
the glutamate pathway by blocking nitric oxide induced neurotox-
icity. Hyperactivity of glutamatergic neurotransmission [possibly
caused by hypofunction of N -methyl-d-aspartate (NMDA) recep-
tors] has been found in schizophrenia (36). Stimulated by gluta-
mate, the NMDA receptors activate production of nitric oxide.
The authors found improvement on a spatial recognition mem-
ory task after minocycline administration, added to antipsychotic
treatment. Task performance showed a decrease after 10 weeks, but
compared to baseline, performance improved at the final assess-
ment. The drop-out rate in this study was high (due to adverse
events and non-adherence) and although it did not differ between
the two treatment groups, this could have biased the results.
To summarize, results regarding visual learning and memory
are inconclusive. At present, there is some evidence for a role of the
serotonin 5-HT3a receptors in this cognitive domain. 5-HT1a and
sigma-1 receptor agonist on the other hand, did not yield promis-
ing results. Additionally, minocycline was found to have positive
effects on visual learning memory when added to antipsychotic
treatment. Both typical and atypical antipsychotics do not seem to
enhance visual learning and memory. Studies investigating nico-
tinic receptor agonist, acetylcholinesterase inhibitors, GABA α2/α3
agonist, psychostimulants, and GR antagonist did not yield pos-
itive results but are in need of replication as they were possibly
underpowered. Overall, results need be interpreted with care as
the described studies are often small pilot studies with inherent
limitations.
WORKING MEMORY
Working memory refers to a system with limited capacity for tem-
porary storage and manipulation of information, necessary for
cognitive tasks (74), and has been the subject of many studies
investigating cognition in schizophrenia. Most of these studies
focused on the effects of antipsychotic medication on working
memory.
Although results are inconclusive at present, both typical and
atypical antipsychotics show little beneficial effects on working
memory. Rollnik et al. (69) compared the effectiveness of typi-
cal and atypical antipsychotics and found no differences between
the two groups. Quetiapine and amisulpride, which both have
low affinity for the 5-HT2a receptors, improved performance on
a verbal working memory task compared to risperidone, olan-
zapine, and clozapine (high affinity for 5-HT2a) treatment (17).
However, performance on a visual working memory tasks did not
significantly improve in both groups. No differences were found in
working memory performance between amisulpride and olanzap-
ine by Wagner et al. (16). However, working memory performance
did improve in both groups. Effects of olanzapine, risperidone,
and haloperidol were compared by Purdon et al. (20). After cor-
rection for multiple comparisons, no significant differences were
found between the three treatment conditions and working mem-
ory did not improve in any group. Mori et al. (75) examined
the effects of switching from typical antipsychotics to olanzapine,
quetiapine, risperidone, or perospirone on working memory and
found improvement in working memory with risperidone, while
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working memory performance of the patients treated with que-
tiapine decreased. Working memory performance did not change
in the olanzapine and perospirone group. It must be noted that
the mean age in the sample was high (59.9 years) and correlated
negatively with working memory scores. Therefore age related
cognitive decline may have confounded these results. On the con-
trary, Kivircik Akdede et al. (26) found improvement on working
memory with quetiapine. However, this study did not include a
control group and did not correct for possible practice effects.
Risperidone treatment was found to be superior to haloperidol
in the study by McGurk et al. (70), but after correcting for anti-
cholinergic co-medication, this effect was no longer significant.
Working memory performance did not improve in both groups.
Paliperidone treatment was not superior to risperidone treatment
in enhancing working memory in the study by Kim et al. (31) and
working memory did not improve in both groups.
Results regarding clozapine are inconclusive. Papageorgiou
et al. (76) compared the effects of clozapine and olanzapine on
working memory and found that working memory improved in
both groups. No differences were found between the two treat-
ment conditions. Ertugrul et al. (33) conducted two working
memory tasks (Digit Span Test and the Auditory Consonant Tri-
gram Test) and found that performance on the Digit Span test
improved with clozapine treatment, whereas performance on the
Auditory Consonant Trigram Test did not. Both studies did not
correct for possible practice effects or multiple testing. These
results are contradicted by Purdon et al. (32) who did not find
improvement in working memory with clozapine treatment. This
discrepancy in findings could be due to methodological short-
comings and differences such as different test batteries and trial
duration.
Riedel et al. found that aripiprazole did not significantly
enhance working memory (39). Aripiprazole also did not improve
working memory when added to atypical antipsychotics (42).
Adjunctive sertindole, an atypical antipsychotic with high affin-
ity for the D2 and 5-HT2a receptors, did not improve working
memory in patients treated with clozapine (77). Finally, working
memory did improve after 20–30 mg of the novel antipsychotic
BL-1020 (a dopamine antagonist with GABA agonistic properties)
compared to placebo whereas 10 mg BL-1020 and risperidone did
not (35).
Hence, although results are preliminary and inconclusive, at
present no convincing evidence is available for the effectiveness of
both typical and atypical antipsychotics on working memory in
schizophrenia. However, the antipsychotic BL-1020 was found to
improve working memory, possibly through its GABAA agonistic
properties.
Single administration of the dopamine D1 agonist dihydrexi-
dine did not enhance working memory in a trial by George et al.
(48). Given the small sample size and the fact that dihydrexidine
was only administered a single time, beneficial effects of long
term dihydrexidine administration on working memory cannot
be ruled out.
Serotonin 5-HT3a receptors seem to be less important for
working memory functioning. Both Akhondzadeh et al. (43) and
Levkovitz et al. (44) found no improvement in working mem-
ory with adjunctive ondansetron (5-HT3a antagonist) treatment.
Moreover, adjunctive tropisetron treatment also did not enhance
working memory (45).
In addition, Niitsu et al. (71) found no improvement in work-
ing memory after adjunctive fluvoxamine treatment. Moreover,
12 weeks of adjunctive citalopram treatment did not enhance
working memory (47). Hence, these results suggest that serotonin
modulation pharmacological agents do not significantly enhance
working memory in schizophrenia.
Both the selective nicotinicα4β2 receptor agonist AZD3480 and
the partial nicotinic α7 agonist DMXB-A did not enhance work-
ing memory performance (51, 52). Acetylcholinesterase inhibitors
donepezil and rivastigmine did not enhance working memory
either (50, 53–55, 57, 58, 77). Jacobsen et al. (78) examined the
effects of a single administration of nicotine [nicotinic acetyl-
choline receptor agonist (79)] on working memory in tobacco
using patients and tobacco using healthy subjects. Although
patients performed significantly worse on the N-back task com-
pared to healthy controls, nicotine administration did improve
performance on the two-back in patients while performance of the
healthy controls declined. Thus, although the acetylcholinesterase
inhibitors donepezil and rivastigmine and nicotinic receptor ago-
nists do not show positive effects on working memory in schizo-
phrenia, positive results were found with a single dose of nicotine
administration. Therefore, a role of acetylcholine and nicotinic
receptors in enhancing working memory cannot be ruled out.
Working memory did not improve in a study by Buchanan et al.
(59) after 4 weeks of treatment with partial GABA α2/α3 agonist
MK-0777. Menzies et al. (80) studied the effects of lorazepam,
a GABAA receptor agonist, and flumazenil, a GABAA receptor
antagonist, on working memory in patients and healthy subjects.
Working memory performance declined after a single dose of
lorazepam whereas performance did not change significantly after
flumazenil. Thus, although results are inconclusive, there is some
evidence that in GABAA agonists may lower working memory.
However positive effects on working memory were found with an
antipsychotic with additional GABAA agonistic properties.
Friedman et al. (60) found no effects of atomoxetine (norepi-
nephrine reuptake inhibitor) on working memory in patients. A
lack of effect could be due to insufficient power.
Glutamatergic pathways have been examined by Duncan et al.
(81). They added 50 mg of d-cycloserine, an antituberculous drug
which, at low doses has agonistic properties at the NDMA recep-
tors, to typical antipsychotics. After 4 weeks of treatment, working
memory did not improve. However, these results need to be repli-
cated before the role of NMDA receptors in working memory can
be established.
Armodafinil, a longer-lasting isomer of modafinil, did not
enhance performance on working memory task when added to
atypical antipsychotics for 4 weeks (61). However, Turner et al.
(63) found that a single dose of modafinil improved performance
on a verbal working memory task compared to placebo. Perfor-
mance on a spatial working memory task did not differ between
modafinil condition and placebo condition. These results were
not replicated by Spence et al. (82) who did not find differences
in performance on a (verbal) working memory task after a single
administration of modafinil compared to placebo. This discrep-
ancy in findings could be due to differences in modafinil dose (200
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and 100 mg, respectively). Moreover, both studies used different
tasks which make direct comparison of results difficult. Nonethe-
less, a single dose of modafinil might enhance working memory
in schizophrenia patients, although recurrent treatment with a
longer-lasting variant showed no effect.
Add-on intranasal oxytocin treatment did not improve working
memory (15). Furthermore, adjunctive mifepristone (GR antago-
nist) treatment did not enhance working memory (66). Goff et al.
(67) did not find improvement in working memory after both
50 and 100 mg sildenafil administration. Furthermore, daily crea-
tine administration added to antipsychotic treatment did not have
beneficial effects on working memory either (65). Add-on minocy-
cline treatment on the other hand, improved working memory in
a study by Levkovitz et al. (73); the number of errors on a work-
ing memory task decreased significantly in the minocycline group
whereas the number of errors in the placebo group increased.
However, this study has some limitations which are described ear-
lier. Thus, apart from minocycline, other lines of research did not
identify possible new intervention strategies for working memory
enhancement in schizophrenia.
To summarize, even though some positive results were found
with minocycline, nicotine, and modafinil, the presently avail-
able studies did not identify promising molecular targets for
enhancement of working memory in schizophrenia. GABA ago-
nists have shown mixed results. Most of the studies examined the
effects of antipsychotic treatment on working memory and only
a limited number of studies used other pharmacological inter-
ventions, which makes it difficult to draw definite conclusions.
More research needs to be conducted, especially on the poten-
tial role of GABA, norepinephrine, acetylcholine, glutamate, and
psychostimulants.
ATTENTION AND VIGILANCE
The construct of attention refers to a core cognitive function that
relates to the ability to select, filter, focus, and process different
stimuli in the environment. Attention is closely related to working
memory and executive functioning (83) and therefore, it is diffi-
cult to distinguish between these constructs. Because of the broad
definition, impairment in virtually any task can be considered as
impairment in attention (83). Therefore, in this review, we only
included articles which used the Continuous Performance Test
(CPT) to specifically measure attention as this test is recommended
by the MATRICS (84).
Studies using antipsychotics to enhance attention report little
beneficial effects. The theory that atypical antipsychotics are supe-
rior to typical antipsychotics in enhancing cognition was tested for
attention as well. A trial comparing olanzapine to amisulpride did
not find differences in effects on attention; attention did not signif-
icantly improve in both groups (16). Olanzapine did not enhance
attention in a study by Molina et al. (85), who examined the
effects of switching from typical antipsychotics or risperidone to
olanzapine. Attention did not improve with olanzapine treatment.
The effects of risperidone on attention were compared to the
effects of respectively haloperidol (86) and quetiapine (23). In the
study of Liu et al. (86) no improvement was found in both the
haloperidol and the risperidone group. Additionally, although no
differences were found between the risperidone and quetiapine
in the study by Harvey et al. (23), within group analyses showed
significant improvement in attention in the risperidone group,
whereas the quetiapine group did not improve. Kim et al. (27)
reported improvement with depot risperidone. However, paliperi-
done did not improve attention (31). To summarize, both typical
and atypical antipsychotics have shown little beneficial effects on
attention in schizophrenia patients.
The possible role of dopamine and serotonin in attention
has also been examined with intervention strategies other than
antipsychotic treatment. George et al. (48) examined the effects
of a full dopamine D1 agonist, dihydrexidine but found it not to
enhance attention.
Studies using serotonin intervention strategies have not yielded
positive results either. Golightly et al. (87) examined the role of
serotonin in attention by using acute tryptophan, a precursor for
serotonin, depletion. Depletion had no effect on performance on
the CPT. Niitsu et al. (71) investigated the effect of adjunctive
fluvoxamine treatment on attention and found no improvement
in attention either. The effects of citalopram, added to treatment
with atypical antipsychotics was examined by Friedman et al. (47).
They found that adjunctive citalopram treatment did not enhance
attention. Thus, although serotonin has been implicated in both
verbal and visual memory, it does not seem to play a prominent
role in attention.
Based on results of mostly preliminary studies, acetylcholine
does not seem to play an important role in attention. Selec-
tive nicotinic α4β2 receptor agonist AZD3480, did not enhance
attention in a study by Velligan et al. (51). Nonetheless, Freed-
man et al. (52) found some beneficial effects of partial nico-
tinic α7 agonist DMXB-A on attention. In their cross-over study,
patients were treated with 75, 150 mg DMXB-A, and placebo. All
treatment arms lasted 4 weeks, followed by a 1-week washout
period. Over the course of the trial, attention improved in all
treatment groups. The authors suggested that possible practice
effects had obscured the potential effect of treatment, and there-
fore also examined the scores after the first 4 weeks of treatment.
They found that attention improved with both doses of DMXB-
A compared to the placebo. Two types of acetylcholinesterase
inhibitors, rivastigmine, and donepezil, did not enhance attention
in schizophrenia (56, 58, 88). On the other hand, a single nico-
tine administration improved attention in schizophrenia patients
but not in healthy controls (89). Thus, despite negative results
with acetylcholinesterase inhibitors, some promising results have
been obtained with nicotine and a partial nicotinic α7 agonist.
These preliminary results suggest that the nicotinic receptors are
a potential target for enhancement of attention in schizophrenia.
Partial GABA α2/α3 agonist MK-0777 did not enhance atten-
tion when added to antipsychotic treatment (59). However, as
mentioned earlier, MK-0777 is a weak GABA α2/α3 agonist and
this is the only study investigating the potential role of GABA
in attention in schizophrenia. Therefore, these results need to
be replicated using specific and more potent GABA modulatory
agents.
Other lines of research have not yielded positive results. The
psychostimulant drug armodafinil did not enhance attention (61).
Furthermore, adjunctive mifepristone (GR antagonist) therapy
did not improve attention (66). Duncan et al. (81) found no
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improvement in attention with adjunctive d-cycloserine treat-
ment. Also, sildenafil (PDE5 inhibitor) did not enhance attention
in schizophrenia in a trial by Goff et al. (67). Stone et al. (68) com-
pared the effects of single administration of glucose to placebo
in clozapine-treated patients and found attention to be signifi-
cantly worse in the glucose condition. Thus, several other lines
of research did not identify potential new intervention strategies
enhancement of attention in schizophrenia.
To summarize, at present only a few pharmacological inter-
vention strategies have been effective in enhancing attention in
schizophrenia. Although results are not consistent, positive results
have been found with both oral and depot risperidone treat-
ment. Furthermore, a partial nicotinic α7 agonist, and a single
administration of nicotine did improve attention in schizophre-
nia, suggesting a role for acetylcholine and nicotinic receptors in
attention. Overall, results need to be considered preliminary and
more research needs to be conducted to replicate these findings as
these studies have some important limitations.
PROCESSING SPEED
Processing speed is considered a core cognitive function and refers
to the speed at which the brain processes information. It can be
measured as the number of correct responses during a task within
a given amount of time (90).
As for other domains of cognition, a majority of the studies
examined the effects of antipsychotic medication on process-
ing speed. The theory that atypical antipsychotics are superior
to typical antipsychotics in improving cognition in patients was
tested for processing speed as well. A study comparing amisulpride
with olanzapine found that processing speed did not improve in
both groups (16). Moreover, performance on a processing speed
task did not differ between patients treated with different typ-
ical antipsychotics and atypical antipsychotics and performance
did not improve in both groups (69). Purdon et al. (20) com-
pared the effects of olanzapine, risperidone, and haloperidol on
processing speed. After correction for multiple comparisons, no
significant differences were found between the three treatment
conditions and processing speed did not improve in any of the
groups. Thus, atypical antipsychotics do not appear to be supe-
rior to typical antipsychotics. Furthermore, no beneficial effects of
the atypical antipsychotic ziprasidone were found on processing
speed (21). Anticholinergics were allowed during the trial which
might have influenced the results. Risperidone depot treatment
did not enhance processing speed in the study by Kim et al. (27).
Moreover, paliperidone ER was not found to be superior to risperi-
done (31). Unfortunately, within group comparisons were not
reported. However, although no significant differences were found
between two treatment groups, risperidone was found to improve
processing speed whereas quetiapine did not in a study com-
paring these two antipsychotics (23). Contrary to those results,
quetiapine was found to enhance processing speed in a trial by
Kivircik Akdede et al. (26). As described earlier, this study did not
include a control group and did not correct for possible practice
effects. These results were not replicated by Purdon et al. (24).
Although processing speed improved in both the quetiapine and
haloperidol group, these results were not significant after cor-
recting for multiple comparisons. Velligan et al. (25) compared
the effectiveness on processing speed between quetiapine and
haloperidol treatment. They found no differences between the
two treatment groups. Purdon et al. (32) found that processing
speed improved with clozapine treatment. However, this improve-
ment cannot reliably be attributed to the effects of clozapine as
the study did not include a control group en they did not cor-
rect for possible practice effects. Beneficial effects of aripiprazole
on processing speed were found by Riedel et al. (39). Yasui-
Furukori et al. (42) found no improvement in processing speed
with adjunctive aripiprazole treatment to olanzapine or risperi-
done. Furthermore, a new antipsychotic with GABAA receptor
agonistic properties in addition to dopamine D2 and serotonin
5-HT2a receptor blockade (BL-1020) did not improve processing
speed (35).
To summarize, both typical and atypical antipsychotics do
not seem to effectively enhance processing speed in schizophre-
nia patients. Although some studies reported positive effects of
clozapine, quetiapine, and risperidone, these results should be
interpreted with care as these studies have important limitations.
Studies examining the role of serotonin in processing speed
did not yield positive results. Adjunctive ondansetron (5-HT3a
receptor antagonist) therapy to antipsychotic medication did not
enhance processing speed in a study by Levkovitz et al. (44).
Adding citalopram to atypical antipsychotic treatment also did
not enhance processing speed in the study by Friedman et al. (47).
In addition, tryptophan depletion did not affect processing speed
in the study by Golightly et al. (87). Thus, the available studies
do not provide evidence for a prominent role of serotonin in pro-
cessing speed in schizophrenia. However, all studies used small
samples and the study of Golightly et al. (87) allowed concomitant
anticholinergics which could have influenced the results.
Studies using acetylcholine related intervention strategies did
not yield positive results either. Both the selective nicotinic α4β2
receptor agonist AZD3480 and the partial nicotinic α7 agonist
DMXB-A did not enhance processing speed (51, 52). Moreover,
three types of acetylcholinesterase inhibitors, donepezil, galant-
amine, and rivastigmine, did not improve processing speed (50,
54–58). Thus, although the role of acetylcholine in memory and
attention has been well established, it does not seem to be a
potential target in enhancing processing speed in schizophrenia.
However, these studies have limitations such as small sample sizes.
Effects of GABA and norepinephrine on processing speed were
also examined. Processing speed did not improve after adjunctive
treatment with partial α2/α3 agonist MK-0777 (59). As mentioned
earlier, BL-1020 (antipsychotic with GABAA agonistic properties)
enhanced antipsychotic also did not enhance processing speed
(35). In the pilot study of Friedman et al. (60), processing speed
did not improve after adjunctive treatment with the norepineph-
rine reuptake inhibitor atomoxetine. Thus, norepinephrine and
GABA α2/α3 receptors do not seem to play an important role in
processing speed in schizophrenia as the available studies were not
able to detect positive effects. However, lack of effect could be due
to the small sample size of both studies.
Processing speed did increase after a single dose of d-
amphetamine in the study of Pietrzak et al. (72). Adjunctive
armodafinil treatment had no beneficial effects on processing
speed in the study by Kane et al. (61). Hence, sinced-amphetamine
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is an indirect dopamine D1 agonist, dopamine D1 receptors
could be a possible target for enhancing processing speed in
schizophrenia although the study by Pietrzak et al. (72) needs
replication.
Lastly, there are some studies of agents that have no direct
(known) effect on neurotransmission. Processing speed did not
improve after single dose of 50 and 100 mg sildenafil (a PDE5
inhibitor commonly used for erectile dysfunction) in the cross-
over trial by Goff et al. (67). Furthermore, adjunctive dehy-
droepiandrosterone (DHEA) therapy, a corticosteroid that serves
as a precursor for both androgenic and estrogenic steroids, did not
enhance processing speed (91). Thus, other lines of research did
not identify promising intervention strategies for enhancement of
processing speed in schizophrenia.
To summarize, at present no convincing evidence exist for the
effectiveness of both typical and atypical antipsychotics on pro-
cessing speed in schizophrenia. Although, positive results were
found with quetiapine, risperidone, clozapine, and aripiprazole,
these studies have important limitations and therefore the effects
cannot be reliably attributed to the effects of the medication.
One positive result was found with single dose d-amphetamine,
suggesting a potential role of dopamine D1 receptors in process-
ing speed. Studies investigating 5-HT3a receptor antagonist, SSRI,
nicotinic receptor agonist, acetylcholinesterase inhibitors, a GABA
α2/α3 agonist, and a norepinephrine reuptake inhibitor did not
find clinically relevant improvement in processing speed but are
in need for replication as the described studies used small samples
and were possibly underpowered.
REASONING AND PROBLEM SOLVING
We found 30 studies that measured reasoning and problem solv-
ing after a pharmacological intervention. Reasoning and problem
solving is considered an aspect of executive functioning. As for
the other cognitive domains, a relatively large number of studies
investigated the effects of antipsychotics on reasoning and problem
solving.
Tyson et al. (17) compared antipsychotics with low affinity for
5-HT2a receptors to antipsychotics with high affinity for these
receptors. Response latency on a reasoning and problem solving
task decreased in the low affinity group, whereas latency increased
in the high-affinity group. The authors did not correct for multiple
comparisons. Since response latency increased in the high-affinity
group, it is not likely that the improvement in the low affinity
group is (only) driven by practice effects. Purdon et al. (20) com-
pared the effects of olanzapine, risperidone, and haloperidol and
found that olanzapine was superior in enhancing reasoning and
problem solving. However, after correcting for multiple compar-
isons, none of the medications improved reasoning and problem
solving. On the contrary, both Kim et al. (27) and Suzuki and
Gen (28) found improvement in performance on a reasoning and
problem solving task. However, Kim et al. (27) did not include
a control group and did not correct for possible practice effects.
Therefore, improvement cannot be reliably attributed to the effects
of medication. Moreover, in the study of Suzuki and Gen (28) a
high percentage of the patients in the haloperidol group was using
concomitant anticholinergics whereas in the risperidone group
anticholinergics were tapered during the first weeks of the trial.
Therefore improvement in this group could be due to effects of
diminishing anticholinergics.
Purdon et al. (24) investigated the effects of haloperidol and
quetiapine and found that reasoning and problem solving did not
improve in both groups. Olanzapine, perospirone, and aripipra-
zole did not improve reasoning and problem solving either (41).
Moreover, adding aripiprazole to atypical antipsychotics also did
not yield positive results (42). Furthermore, no improvement was
found with clozapine by Ertugrul et al. (33) and Purdon et al.
(32). Nielsen et al. (77) added sertindole to clozapine but found
no improvement in reasoning and problem solving either. Finally,
the new antipsychotic with GABA agonistic properties BL-1020
also did not improve reasoning and problem solving (35). Hence,
although positive results were found with risperidone depot, both
typical and atypical antipsychotics have shown little clinically
relevant effects on reasoning and problem solving.
Serotonergic intervention strategies have not yielded positive
results. Adjunctive ondansetron (5-HT3 antagonist) treatment
had no beneficial effects on reasoning and problem solving (43).
Fluvoxamine and citalopram both did not enhance reasoning
and problem solving either (47, 71). On the contrary, Golightly
et al. (87) found that patients who underwent tryptophan deple-
tion during the first session performed significantly worse on the
Wisconsin Card Sorting Test (WCST) compared to placebo. How-
ever, this effect was not present during the second session. The
WCST requires subjects to sort cards by a certain parameter.
The subject is not told which parameter. The sorting princi-
ple changes after 10 correct responses in a row. Thus subjects
have to acquire a certain strategy to sort the cards. The authors
concluded that tryptophan depletion only affected strategy acqui-
sition and that once this is learned; tryptophan depletion did
not interfere with application of this strategy. Thus, based on
the results described above, 5-HT3a antagonist and SSRI’s did
not effectively enhance reasoning and problem solving. How-
ever, a role for serotonin in this aspect of cognition cannot be
ruled out since tryptophan depletion did interfere with strategy
acquisition.
Partial nicotinic α7 agonist DMXB-A had no enhancing effects
on reasoning and problem solving in the study by Freedman et al.
(52). In addition, studies investigating the effects of the acetyl-
cholinesterase inhibitors donepezil and rivastigmine did not find
improvement in performance on a reasoning and problem solv-
ing task either (50, 53, 56, 58). Hence, based on these results,
nicotinic α7 agonists and acetylcholinesterase inhibitors do not
appear to significantly enhance reasoning and problem solving in
schizophrenia.
In line with the results of Geffen et al. (35) described earlier, no
positive results were obtained with other GABAergic interventions
strategies. Adjunctive therapy with partial GABA α2/α3 agonist
MK-0777 did not enhance reasoning and problem solving abili-
ties in the study by Buchanan et al. (59). In addition, adjunctive
topiramate (an antiepileptic drug which potentiates GABAergic
transmission probably through its AMPA/kainite receptor antag-
onistic properties) treatment did not enhance reasoning and
problem solving either (92). Zoccali et al. (93) examined the
effects of adjunctive lamotrigine, an anticonvulsant drug which
reduces excessive glutamate release in the brain via inhibition of
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voltage-gated sodium and calcium channels (94). Reasoning and
problem solving did not improve.
The potential role of norepinephrine in reasoning and problem
solving in schizophrenia was examined in a pilot study by Fried-
man et al. (60) by adding atomoxetine to antipsychotic treatment.
They found no improvement in this aspect of cognition.
In conclusion, the available evidence suggests that modulation
of GABA and glutamate transmission and norepinephrine reup-
take inhibition does not have enhancing effects on reasoning and
problem solving abilities in schizophrenia.
Some positive results have been found with psychostimu-
lant drugs. Compared to placebo, performance on a reasoning
and problem solving task improved after a single dose of d-
amphetamine [indirect dopamine D1 agonist, (72)]. Contrary to
these results, Turner et al. (63) found that, compared to placebo,
response latency on the Tower of London task was significantly
lower after modafinil administration. The number of attempts
to obtain the correct solution did not differ between the two
groups. Armodafinil, the longer-lasting isomer of modafinil, did
not affect reasoning and problem solving abilities (61). Thus,
although armodafinil and modafinil did not enhance reasoning
and problem solving, d-amphetamine did improve this aspect of
cognition. This suggests that dopamine D1 agonists are a poten-
tial area of research for further study of reasoning and problem
solving in schizophrenia.
Pharmacological intervention strategies that do not directly
influence neurotransmission were also investigated. Levkovitz
et al. (73) found that reasoning and problem solving abilities
improved after add-on minocycline treatment whereas perfor-
mance in the placebo group did not change. Both creatine and
glucose had no enhancing effects on reasoning and problem solv-
ing; daily creatine administration in addition to antipsychotic
treatment did not have beneficial effects on working memory
in the study by Kaptsan et al. (65). Stone et al. (68) found no
improvement in reasoning and problem solving after a single dose
of glucose. Hence, despite of the study’s limitations, minocycline’s
putative ability to improve reasoning and problem solving abilities
should be studied further.
In conclusion, although positive results were found with
depot risperidone treatment in studies with important limita-
tions, antipsychotics do not seem to effectively improve reasoning
and problem solving in schizophrenia. The available studies did
not show enhancing effects of the neurotransmitters serotonin,
acetylcholine, GABA, or norepinephrine on reasoning and prob-
lem solving. However, dopamine D1 agonists may have potential
in this cognitive domain since one positive result was found with
a single dose d-amphetamine. Finally, minocycline had enhanc-
ing effects on reasoning and problem solving abilities. However,
this study has important limitations. Therefore these results are in
need for replication.
SOCIAL COGNITION
In general terms, social cognition refers to the cognitive processes
used to decode and encode the social world (95). Of all the
MATRICS cognitive domains, social cognition has received the
least attention in research. This is probably due to the fact that
it is a relatively new area in schizophrenia research (96) and that
the boundaries of this domain are not entirely clear (96). Final
screening yielded no more than seven articles on social cognition
and pharmacology using validated outcome measures.
A study by Mizrahi et al. (97) examined the effects of antipsy-
chotic treatment on social cognition in schizophrenia. They inves-
tigated the effects of clozapine, risperidone, olanzapine, and loxap-
ine on Theory of Mind (TOM). TOM is an aspect of social cogni-
tion which refers to the ability to understand intentions of others
and to recognize that their actions are guided by beliefs about
the world (97). They found that TOM improved after 2 weeks of
medication use and continued to improve during the rest of the
trial. Unfortunately, the authors did not differentiate between the
four different antipsychotics. However, all four types of medica-
tion have high affinity for dopamine D2 receptors as well as the
5-HT2a receptors (98, 99). These results are in line with the results
of Sumiyoshi et al. (100) who found that perospirone treatment
improved performance on a social cognition task. Nonetheless,
both studies did not include a control group and used small sam-
ples. Hence, given the longitudinal design of this study, natural
progression and practice effects cannot be excluded. Addition-
ally, the high drop-out rate in the study of Sumiyoshi et al. (100)
could have led to a bias in the sample. Behere et al. (101) found
that performance on an emotion recognition task improved after
risperidone treatment. However, it must be noted that they did
not include a control group and that time of follow-up assessment
was not equal for all patients. Opposed to these results, the study
by Harvey et al. (23) discussed earlier did not find improvement in
performance on an emotional recognition task in patients treated
with either quetiapine or risperidone.
Hence, these results imply preliminary evidence that dopamine
and serotonin are important for TOM related aspects of social
cognition but not for emotion recognition.
The possible role of GABA in social cognition was investigated
by Buchanan et al. (59). They found no improvement with the par-
tial GABA α2/α3 agonist MK-0777 when added to antipsychotic
treatment. The psychostimulant armodafinil also did not improve
social cognition (61). Hence, GABA α2/α3 receptors are not prime
candidates for enhancing social cognition in schizophrenia.
Another line of research focused on the role of oxytocin in social
cognition. This neuropeptide is known for its role in positive social
behavior (102). Pedersen et al. (103) found that intranasal oxy-
tocin administration improved social cognition. This implicates
a role for oxytocin in social cognition. Since previous research
showed that plasma oxytocin levels are lower in schizophrenia
compared to controls (104), it could be hypothesized that increas-
ing oxytocin levels improves social cognition in schizophrenia.
However, the study of Pedersen et al. (103) has some important
limitations. First, the sample size was small. Moreover, they car-
ried out multiple tests in this small sample; therefore the results
have to be interpreted with caution. Studies investigating the role
of oxytocin in social cognition are sparse. Therefore, to determine
the exact role of oxytocin in social cognition more research needs
to be conducted on this topic.
In conclusion, the available seven studies suggest preliminary
evidence for a role of dopamine, serotonin, and oxytocin in social
cognition in schizophrenia patients. GABA does not seem to be a
promising target for enhancement of social cognition. However,
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these studies have important limitations. Therefore future research
needs to confirm the role of these transmitters in social cognition.
DISCUSSION
With this review we aimed to provide an outline of the underly-
ing neuropharmacological mechanisms of the separate MATRICS
domains. Although some potential targets were identified, over-
all, results of previous studies attempting to identify potential
pharmacological targets for cognitive enhancement have been
unsatisfactory. This review has shown that dysfunction in separate
cognitive domains seems to arise from different underlying neu-
ropharmacological mechanisms. This suggests that schizophre-
nia patients with different cognitive impairments could benefit
from different (adjunctive) pharmacological agents. The iden-
tified potential molecular targets, which include dopamine D1
receptors, serotonin 5-HT1a and 5-HT3a receptors, nicotinic α7
receptors, GABAA receptors, and NMDA receptors, are described
more extensively below.
DOPAMINE D1
Although George et al. (48) were not able to detect positive results
with a single dose of D1 agonist dihydrexidine, Pietrzak et al. (72)
found improvement in both processing speed and reasoning and
problems solving abilities (both aspects of executive functioning)
after a single dose of d-amphetamine, an indirect D1 agonist.
Decreased dopaminergic neurotransmission in the PFC has been
hypothesized to be associated with cognitive dysfunction in schiz-
ophrenia (36). Since D1 receptors are highly abundant in the PFC
(105), this receptor subtype has been particularly associated with
executive function and working memory. A PET study by Okubo
et al. (106) found decreased D1 receptors in the PFC in schizo-
phrenia which was indeed associated with poorer executive func-
tioning. Animal studies provide additional evidence for cognitive
enhancing effects of D1 receptor agonists as low doses of several
D1 agonists were found to enhance cognition in non-human pri-
mates (107, 108). Because a majority of dopamine receptors in the
PFC belong to the D1 subtype, and not to the D2 subtype (109),
which is related to psychotic symptom severity, D1 receptors may
be a feasible molecular target for enhancement of executive func-
tion related aspects of cognition without exacerbation of psychotic
symptoms.
SEROTONIN 5-HT1a AND 5-HT3a RECEPTORS
(Partial) 5-HT1a receptor agonism was found to improve verbal
learning and memory (38–40). These enhancing effects may be
due to the high density of 5-HT1a receptors in the hippocam-
pus (36), which is an area in the brain well known for its role
in memory. In addition, preclinical studies showed that both 5-
HT1a agonists and antagonist enhanced cognition in rats (110,
111). 5-HT3a receptor antagonism was associated with improve-
ment in visual learning and memory (43, 44). Contrary to other
subtypes of serotonin receptors, the 5-HT3a receptor is the only
ligand-gated ion channel subtype (43). To date, not many studies
investigated the potential role of 5-HT3a receptors in cognition.
However, since both Akhondzadeh et al. (43) and Levkovitz et al.
(44) found improvement in visual learning and memory with the
5-HT3a receptor antagonist ondansetron, these receptors might be
a promising molecular target for enhancement of visual learning
and memory in schizophrenia.
ACETYLCHOLINE NICOTINIC α7 RECEPTORS
The role of acetylcholine in cognition (particularly in learning,
memory, and attention) has been widely established and cen-
tral dysfunction of the cholinergic system has been found to be
associated with cognitive symptoms in neurological diseases as
Alzheimer and Parkinson’s disease (112–114). However, with the
exception of positive results found with nicotine and a partial
nicotinic α7 agonist on attention (52, 89), cholinergic interven-
tions strategies did not affect any of the cognitive domains in
the available studies. However, all the available studies that met
the inclusion criteria used acetylcholinesterase inhibitors or nico-
tinic agonists. Although (mostly post-mortem) both nicotinic and
muscarinic receptor abnormalities have been repeatedly found in
schizophrenia (115–120), nicotinic receptor antagonists do not
appear to impair cognition in the same manner as antimuscarinic
drugs (121). This might explain the lack of improvement in the
described studies. Indeed, a small pilot study by Shekar et al. (122)
found that the muscarinic receptor agonist xanomeline improves
verbal, visual, and working memory in patients with schizophrenia
or schizoaffective disorder. Moreover, xanomeline improved cog-
nition in Alzheimer disease (123). Thus, although positive effects
on attention were found with nicotine and a partial nicotinic α7
agonist, future studies should focus on muscarinic agents.
GABAA RECEPTORS
Both GABAA receptor antagonists and agonists were found to
affect working memory and verbal learning and memory (35,
80). Multiple studies have shown reduced GABAergic transmis-
sion, especially in the PFC, in schizophrenia (124). The PFC is
strongly involved in working memory functioning (125) and ani-
mal studies have shown that appropriate GABA transmission in
the dorsolateral prefrontal cortex (DPFC) is essential to adequate
working memory functioning (36, 126). Lewis et al. (37) showed
that altered GABA transmission in the DPFC is possibly limited to
certain cell classes, such as the chandelier cells, which synchronize
the activation of the pyramidal neurons via the GABAA recep-
tor subtypes. Therefore, GABAA receptors may be a promising
molecular target for enhancement of working memory.
GLUTAMATE NMDA RECEPTORS
Glutamate, the primary excitatory neurotransmitter in the mam-
malian brain, has been linked to learning and memory because
of its principal role in modulating long-term potentiation (127),
and hyperactivity of glutamatergic neurotransmission has been
implicated in schizophrenia (36). It has been hypothesized that
cognitive dysfunction in schizophrenia is due to hypofunction of
the NMDA receptor (81). Small increases in NMDA-dependent
glutamate transmission might enhance cognition, whereas exces-
sive stimulation might have neurodegenerative consequences (36).
Activation of the NMDA receptors leads to synthesis of nitric
oxide,which is able to further increase the excitotoxicity by increas-
ing glutamate release from presynaptic neurons and inhibition
of glial glutamate transporters (73). Indeed, minocycline (which
blocks nitric oxide induced neurotoxicity) was found to improve
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visual learning and memory, working memory, and reasoning
and problem solving abilities (73). Although d-cycloserine (which
non-competitively enhances NMDA neurotransmission) was not
found to improve attention and working memory (81), phar-
macological agents reducing the neurotoxic effects of extensive
glutamate might still be a promising intervention strategy for
cognitive enhancement.
CAN THE NEGATIVE RESULTS BE EXPLAINED BY STUDIES
LIMITATIONS?
A substantial number of the studies evaluated in this review
addressing pharmacological cognitive enhancement in schizo-
phrenia report negative results. It is debatable whether this is due
to ineffectiveness of the agents used, or that potential results were
obscured by methodological shortcomings as cognition research
in schizophrenia deals with pertinent limitations. First, in many of
the studies included in this review, cognition was not the primary
outcome parameter. As a result, the design of these studies was not
always optimal to measure cognitive enhancement. Second, the
sample sizes are often too small to detect clinically relevant effects.
Third, concurrent medications may interfere with the investigated
pharmacological agents. Patients with schizophrenia are gener-
ally treated with antipsychotics. Because the entire mechanism
of action of these medications is not completely understood, it
cannot be ruled out that antipsychotics alter the effects of the
added agents (62). Moreover, patients often use concomitant
medications such as benzodiazepines, antidepressants, and anti-
cholinergics, which could influence the effects of the adjunctive
pharmacological agents as well. Especially anticholinergic med-
ication is well known for its adverse effects on cognition (29).
Therefore, studies including only medication-naïve patients at
early stages of the disease are necessary. Fourth, studies often do
not use fixed doses. It is possible that certain agents are only
effective in a certain dose. If studies do use a fixed dose, this
dose is often established for treating the illness or symptoms it
was originally used for. However, it is not necessarily so that the
same dose is required for cognitive enhancement in schizophre-
nia. Fifth, research seems to focus on the direct or semi-direct
enhancing effect of modulating certain receptors while cogni-
tive decline has most often been a process of a longer period of
time possibly implying that enhancement studies should equally
allow for more time to yield effects. Also, different paradigms
could focus on neuroprotective targets and preventing cognitive
decline early in the disorder in contrast to enhancing cogni-
tion after impairment. Sixth, not all studies report information
about substance use of the participants. Patients with schizo-
phrenia often abuse substances as tobacco, alcohol and cannabis,
and epidemiological studies found high co-morbidity rates of
substance abuse (40–60%) (128, 129). Particularly tobacco use
can interfere with nicotinic receptor agents as it causes desensi-
tization of this receptor subtype. Although most of the studies
excluded patients with a (recent) co-morbid diagnosis of alcohol
or drug abuse/dependence, tobacco using patients are almost never
excluded. Seventh, studies often use different neuropsychological
tasks to measure the same aspects of cognition which makes it
difficult to compare the results. Therefore, studies should use a
standardized cognitive battery, such as the MATRICS Consensus
Cognitive Battery [MCCB; (84)] or the CANTAB cognitive battery
(130). The MCCB in particular, has been composed to reliably
assess cognition in schizophrenia patients. At present, only three
of the reported studies used this battery to measure cognition
(50, 52, 59). Finally, not all studies used a control group and
repeatedly conducted the same test battery without adequately
correcting for potential practice effects. Therefore, improvement
often cannot be reliably attributed to the effect of the pharma-
cological agent. Future research should take these limitations in
to account in experimental setup and optimize their design for
cognition measurement. Ideally, future studies should include a
placebo or other control group and should ensure sufficient power
by including enough participants. Furthermore, medication-naïve
patients should be recruited, preferably non-smokers who do not
use other substances as cannabis and alcohol. Regarding the design,
future studies should choose cognition as primary outcome mea-
sure and optimize the design by using a fixed dose and make sure
to choose a dose suitable for schizophrenia patients. Finally, future
studies should make sure to choose sufficient trial duration and
to use a standardized cognitive test battery which covers all the
MATRICS domains. In this manner, studies will be better com-
parable and the effects of possible confounding variables will be
limited. To summarize, the negative results of “pharmacological
cognitive enhancement studies” could partially be explained by
studies’ limitations.
CONCLUSION
Although some potential targets were identified, overall, results of
previous studies attempting to identify potential pharmacological
targets for cognitive enhancement have been disappointing. This
review has shown that dysfunction in separate cognitive domains
may arise from different underlying neuropharmacological mech-
anisms which suggests that schizophrenia patients with different
cognitive impairments could benefit from different intervention
strategies. Although development of effective cognitive enhancers
is a complex process, it is an exciting challenge for this area of
research as improvement of cognition contributes significantly to
the quality of life of these patients.
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